Genvor Inc (GNVR)
| Market Cap | 27.31M-62.5% |
| Revenue (ttm) | n/a |
| Net Income | -3.45M+41.0% |
| EPS | -0.09+66.7% |
| Shares Out | 36.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,866 |
| Open | 0.75 |
| Previous Close | 0.75 |
| Day's Range | 0.75 - 0.75 |
| 52-Week Range | 0.01 - 2.00 |
| Beta | 558527.20 |
| Analysts | none |
| Price Target | n/a |
| Earnings Date | n/a |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About GNVR
Genvor Incorporated develops plant-based defense technology designed to help farmers achieve global food security. The company provides antimicrobial peptide technologies through the BioCypher platform by designing and validating minimum viable products and expanding its collaborations to include foliar application models, seed traits, and seed treatment platforms. The company has a strategic collaboration with Canlab International for the development, manufacturing, and commercialization of a portfolio of novel natural peptide candidates targeting weight management, anti-aging and longevity, tissue repair and regeneration, hair restoration, and hormonal optimization. Genvor Incorporated is based in Henderson, Nevada.
Ask Barron about GNVR
$GNVR stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in GNVR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GNVR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GNVR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New GNVR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GNVR from public contracts
Source: USAspending.gov
GNVR Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from GNVR’s recent data — informational, not investment advice